Disc Medicine, Inc. Payments to Acquire Marketable Securities
Disc Medicine, Inc. (IRON) reported Payments to Acquire Marketable Securities of $186.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-30
- Disc Medicine, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $92.73M, a 58.17% increase year-over-year.
- Disc Medicine, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $93.76M, a 73.00% decline year-over-year.
- Disc Medicine, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $358.27M, a 392.29% increase year-over-year.
- Disc Medicine, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $85.44M, a 9.21% decline year-over-year.
- Disc Medicine, Inc. payments to acquire marketable securities for fiscal 2025 was $849.59M, a 119.74% increase from fiscal 2024.
- Disc Medicine, Inc. payments to acquire marketable securities for fiscal 2024 was $386.63M.
- Disc Medicine, Inc. payments to acquire marketable securities for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $92.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $186.49M 10-Q · filed 2026-07-30 | $544.77M derived: sum of 3 quarters · filed 2026-07-30 | $630.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $93.76M 10-Q · filed 2026-05-05 | $452.04M derived: sum of 2 quarters · filed 2026-05-05 | $537.47M derived: sum of 3 quarters · filed 2026-05-05 | $596.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $358.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $443.71M derived: sum of 2 quarters · filed 2026-02-26 | $502.33M derived: sum of 3 quarters · filed 2026-07-30 | $849.59M 10-K · filed 2026-02-26 |
| 2025-09-30 | $85.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $144.06M derived: sum of 2 quarters · filed 2026-07-30 | $491.31M 10-Q · filed 2025-11-06 | $564.09M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $58.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $405.88M 10-Q · filed 2026-07-30 | $478.65M derived: sum of 3 quarters · filed 2026-07-30 | $572.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $347.25M 10-Q · filed 2026-05-05 | $420.03M derived: sum of 2 quarters · filed 2026-05-05 | $514.13M derived: sum of 3 quarters · filed 2026-05-05 | $733.88M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $72.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $166.88M derived: sum of 2 quarters · filed 2026-02-26 | $386.63M derived: sum of 3 quarters · filed 2026-02-26 | $386.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $94.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $313.85M derived: sum of 2 quarters · filed 2025-11-06 | $313.85M 10-Q · filed 2025-11-06 | $313.85M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $219.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $219.75M 10-Q · filed 2025-08-07 | $219.75M derived: sum of 3 quarters · filed 2026-02-26 | $219.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |